to, when injected intratumorally, not only degrade the main component of ECM, fibronectin but also inhibit the fibrosis produced by CAFs, thereby reducing tumor stiffness, enhancing perfusion, and alleviating hypoxia (147). The gene discussed is FN1; the disease is neoplasm.